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Abstract
Background: Parkinson’s disease (PD) is the second commonest neurodegenerative disease in developed countries.
Current treatment for PD is pharmacologically focused and can have significant side-effects. There is increasing
interest in holistic approaches including mindfulness to help manage the challenges associated with living with
PD. We hypothesised that there would be an improvement in PD associated function and wellbeing in participants
after participating in a 6-week mindfulness-based lifestyle program, and that these improvements would be sustainable
at 6 months. Our primary objective was to determine changes in function and wellbeing associated with PD.
Methods: An exploratory prospective, mixed-method, randomised control trial incorporating a before and after design
with a waitlist control, with an embedded qualitative component was conducted in 2012–2013. Participants included
community living adults with disability congruent to H&Y Stage 2 PD, aged 18–75, fluent in spoken and written
English and able to attend at least four of six sessions of the program. Participants were randomised to the
intervention or wait-list control groups at two locations. All participants in the wait-list control group eventually
received the intervention. Two randomisation codes were created for each location. Allocation to the intervention or
wait-list control was by random number generation. The program facilitator and participants were blinded to
participant data.
Results: Group 1 included 35 participants and group 2 (the waitlist control), 37. Data was analysed from 24
(group 1) and 33 (group 2) participants. The intervention group, compared to the waitlist control, showed a
small improvement in function and wellbeing associated with PD immediately after the program (t-score = −0.
59) and at 6-month post intervention (t-score = −1.42) as reported by the PDQ-39 SI. However this finding
was not significant (p = 0.56 and 0.16 respectively). A small yet significant effect size (β = 0.23) in PDQ-39 ADL
was reported in group 1 after 6-months post-intervention. This showed a positive improvement in the ADL as
reported by group 1 after 6-months (t-score −1.8, p = 0.04). Four secondary measures are reported.
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Conclusions: Our findings suggest mindfulness-based lifestyle programs have potential to assist participants in
managing the ongoing difficulties associated with a neurological condition such as Parkinson’s disease. Importantly,
our study shows promise for the long term benefits of such programs. Improvements to participant activities in daily
living and mindfulness were retained at 6-months post intervention. A more definitive study should be conducted in
a larger sample of PD patients to further explore these findings and their impact on reducing stress and anxiety
in PD patients.
Trial Registration: Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12612000440820, 17th April 2012.
Keywords: Parkinson’s disease, Neurological disorder, Mindfulness, Group program, Meditation
Abbreviations: ADL, Activities of daily living; BOD, Bodily discomfort; COG, Cognitions; COM, Communication;
DASS, Depression anxiety and stress scales; EMO, Emotional well-being; FMI, Freiberg mindfulness index; H&Y, Hoehn &
Yahr; HBQ, Health behaviours questionnaire; HrQOL, Health related quality of life; LOC, Locus of control; MDB, Mobility;
PD, Parkinson’s disease; PDQ, Parkinson’s disease questionnaire; PV, Parkinson’s victoria; SOC, Social support; STI, Stigma
Background
Parkinson’s disease (PD) is the second commonest neu-
rodegenerative disease in developed countries. [1]. When
adjusted by age, global incidence rates of PD range be-
tween 9.7 and 13.8 per 100,000 population [2]. In 2014
there were nearly 70,000 people living with PD in
Australia, approximately 14,500 more than in 2005, and
5,100 more than in 2011 [3]. With many developed
countries reporting increased ageing populations, the in-
cidence of PD is expected to increase [4, 5]. Despite this
recognition, many diagnosed with PD continue to suffer
poor quality of life, experiencing complex motor and
non-motor symptoms affecting emotional, cognitive and
physical well-being [6].
Where PD is poorly self-managed, symptoms can lead
to significant challenges in completing basic daily activ-
ities. Negative outcomes for people diagnosed with PD
extend beyond the individual or patient level. Large pro-
portions of the burden of disease are carried by those
who care for PD sufferers and economically by health-
systems [2, 7]. These effects can be intensified by complex
and, at times, invasive treatment options. Lifestyle-based
interventions, incorporating mindfulness training, have
been identified as improving self-management outcomes
in patients with a variety of chronic [8–12] and neuro-
logical diseases [13, 14].
Mindfulness is a form of meditation that has been
defined as: “the awareness that emerges through paying
attention on purpose, in the present moment, and non-
judgmentally to the unfolding of experience moment by
moment” [15]. One program for multiple sclerosis, utilising
lifestyle and mindfulness training in conjunction with
conventional medical care, found reduced costs of dis-
ease, reversal of disease progression and improvement
in patient quality of life [16]. Meta-analyses also suggest
longer term improvements in patient mental health
[12]. In more recent years, programs encompassing
mindfulness have begun to explore the neurobehavioral
effects for people living with PD, with positive out-
comes, including improved motor function, patient ex-
perience of pain [17] and development of better coping
mechanisms [18]. The longitudinal benefit of such pro-
grams on the self-management of PD however, to the
best of our knowledge, has not yet been explored.
This study aimed to investigate the impact of a 6 week
mindfulness-based lifestyle program for community liv-
ing adults with Hoehn and Yahr (H&Y) stage two PD
[19]. Our primary objective was to determine changes in
function and wellbeing associated with PD. Secondary
objectives were changes in health behaviours, mental
health, and locus of control.
We hypothesised that there would be an improvement
in PD associated function and wellbeing in participants
after participating a 6 week mindfulness-based lifestyle
program and that these improvements would be sustain-
able at 6 months.
Methods
Study design
The study was an exploratory prospective, mixed-
method, randomised clinical trial incorporating before
and after design with a waitlist control, with an embed-
ded qualitative component. The current paper presents
the study’s quantitative data and findings. Qualitative
findings will be reported separately. The intervention
was participation in a 6-week mindfulness-based life-
style program. All participants in the wait-list control
group eventually received the intervention, but only
after the intervention group. The study was conducted
over 12 months between 2012 and 2013. A detailed
description of the methodology has been previously
published [20].
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Advisory Group
An expert advisory group was formed to provide advice
on recruitment and link clinicians and researchers.
Apart from contributions to the Advisory Group, the
funding body, Parkinson’s Victoria (PV), had no other
involvement in the decisions and procedure concerning
data collection, analysis, interpretation and academic
dissemination.
Setting
The intervention was delivered at two venues, located in
two different inner-urban suburbs of Melbourne, Australia.
Melbourne is a capital city in Australia with over four mil-
lion people. In Australia, there are approximately 80,000
people living with Parkinson’s. In Victoria, more than
2,225 people are newly diagnosed with Parkinson’s every
year [21]. The suburbs chosen for the study were located
close to Parkinson’s Victoria meeting group sites.
Participants
The intervention group were participants attending the
first 6-week mindfulness-based lifestyle program at each
location. The control participants were those on a wait-
list control group at each location. All the control partic-
ipants were invited to attend the same program held at
each site, but only after the intervention participants had
completed the program.
Eligibility criteria were:
 Between the ages of 18 and 70 at the time of
recruitment
 Fluent in spoken and written English
 Able to attend at least four of six sessions of the
mindfulness-based lifestyle program
 Community living adults with disability congruent
H&Y Stage 2 PD [19]. This staging, for the purposes
of the study, was determined by screening participants
using the two below questions developed in
conjunction with a neurologist. To be eligible,
participants had to answer ‘yes’ to both questions:
○ ‘Do you have problems of shaking (tremor),
stiffness or difficulty with movements on both
sides of your body?’
○ ‘Most of the time, can you walk straight and
stand up without assistance?’
Recruitment
Volunteer participants were recruited from the PD
community residing in metropolitan Melbourne. Target
participants were initially invited to participate through
a combination of written invitations from Parkinson’s
Victoria sent to people listed on the Parkinson’s regis-
try, advertisements in PV publications and through
neurologists and primary care clinicians. In order to
assist with the potential issue of slow recruitment, as
seen in previous trials [22], a recruitment officer (BV)
was employed. The recruitment officer worked with the
Advisory Group to develop additional recruitment
strategies, including: the development of promotional
materials (flyers, brochures, and posters), engaging with
PD support groups, presenting at PD community
events and utilising the M.J. Fox Foundations clinical
trial finder [23].
Intervention
The intervention was a mindfulness-based lifestyle pro-
gram involving facilitated, two hour group sessions once
a week for a total of 6-weeks. The program was designed
to introduce key lifestyle and mindfulness elements to
participants. Typically, each session consisted of a 5–20
min mindfulness practice, led by the program facilitator
and author of the model (CH), introduction to one of
the ESSENCE elements (Fig. 1) and an open group dis-
cussion about participants’ thoughts and feelings about
the program. The mindfulness practice included specific
techniques, such as, attention to the breath, a ‘body scan’
and letting go of competing or negative thoughts. Partic-
ipants were further introduced to strategies designed to
help them to live better with a chronic disease and en-
couraged to use aspects of the program that were most
relevant to them.
A 3 disc CD pack with guided mindfulness practices
free-of-charge and printed information was given to par-
ticipants to assist them with their practice outside of the
group sessions. Participants were expected to continue
their usual medical management and monitoring by
their general practitioners and specialists.
Each intervention session was 2 h long and attended
by a research assistant (BV) in addition to the course
facilitator (CH). The research assistant was responsible
for completing the attendance role, collecting observa-
tional data (discussed further below) and preparing the
morning or afternoon tea.
Data collection
Quantitative data
The primary outcome is the change in function and
well-being associated with PD, measured by the vali-
dated Parkinson’s disease Questionnaire (PDQ-39) [24],
which captures information about PD-related symptoms
and wellbeing. The questionnaire has 39 items each on a
scale of 0 (never) to 5 (always or cannot do at all). Eight
dimensions are reported: mobility (MOB) (10 items), ac-
tivities of daily living (ADL) (6 items), emotional well-
being (EMO) (6 items), stigma (STI) (4 items), social
support (SOC) (3 items), cognitions (COG) (4 items),
communication (COM) (3 items), and bodily discomfort
(BOD) (3 items). A summary index score (PDQ-39-SI)
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provides an overall picture of health-related-quality-of-
life (HRQoL).
Secondary outcomes are changes in health behaviours,
mental health and locus of control measured by four val-
idated, self-administered questionnaires. 1. mindfulness
as measured by the Freiburg Mindfulness Inventory (FMI)
[25], 2. depression, anxiety and stress as measured by the
DASS 21 [26], 3. locus of control as measured using the
multidimensional locus of control (LOC), Form B [27],
and 4. exercise and nutrition as measured in the Health
Behaviours Questionnaire (HBQ)) [28].
All participants completed the study questionnaires at
three time points: (T0) baseline, (T1) week 7 after the
intervention participants (but not wait-list controls) had
completed the intervention and (T2) 6 months after the
intervention had completed for all participants (both
intervention and wait-list controls).
Study questionnaires were mailed or given to partici-
pants in person. Questionnaire packages included a self-
addressed return envelope, cover letter with contact
details for the researchers and a request that question-
naires be completed and returned within 1 week. Base-
line (T0) questionnaires were mailed to all participants.
At this time, participants were also emailed a link to an
electronic instructional video, detailing each component
of the questionnaire. Week 7 (T1) questionnaires were
distributed to the intervention participants after the final
session and if a participant was absent then the ques-
tionnaire was mailed. Wait-list control participants re-
ceived the questionnaire in the mail. The 6 month (T2)
questionnaires were all mailed. Follow up strategies were
implemented if a survey was not returned within 2 week
of the sent date, consisting of phone calls and emails to
the participant made by a research assistant. Follow up
was ceased at 4 weeks post sent date.
Other quantitative data
We monitored participant attendance at the weekly
intervention sessions. If a participant did not attend four
or more sessions, this was recorded and their data ex-
cluded from the analysis. We also monitored participant
adherence using a modified medical outcomes study [29]
and by participants self-rating their practice of the pro-
gram exercises in the week prior on a 5-point Likert
scale. Intervention participants were required to complete
the adherence measure prior to leaving the fourth and
Fig. 1 ESSENCE
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final sessions. All participants were mailed the adherence
measure along with the other study questionnaires at the
6-month post intervention point.
Sample size
In order to detect a change in the primary outcome
measure of PDQ-39 having a change degree consistent
with a medium-to-large effect in this study, a sample
size of 80 participants was needed. This calculation as-
sumed a dropout rate of 25 %, which is similar to rates
experienced by other studies involving participants with
PD [22]. See the protocol paper for more information
about the power and sample size calculations [20].
Randomisation
Participants were randomised to either the intervention
or wait-list control groups at each location a week prior
to commencement of the first programme. Two ran-
domisation codes were created for each location. Alloca-
tion to the intervention or wait-list control was by
random number generation (www.randomizer.org) using
the permuted four block method.
Blinding
The programme facilitator (CH) and participants were
blinded to all participant data.
Analysis
Quantitative data
At the 7-week data collection time point, intervention
participants had completed the 6-week intervention but
the wait-list controls had not; therefore analysis at this
stage followed that of a standard two group RCT. This
study used the baseline and 7-week data points and
paired t-tests to examine differences in the outcome
measures. At the 6-month data collection point, all par-
ticipants in both groups had completed the intervention;
therefore we did a before and after paired data analysis
using baseline and 6-month data points to examine any
long-term differences in the outcome measures. Effect
size for the difference between the two groups was cal-
culated using the t-statistic from the t-test using the
pooled variance of the variables [30].
Additionally, outcomes of the programme were corre-
lated with participant scores for adherence using Pearson’s
regression. We set a significance level of alpha = 0.05 for
all outcomes in this exploratory study in order to identify
any trends in the results.
Standard protocol, approvals, registration and patient
consents
The study was approved the Monash University Human
Research Ethics Committee project number CF11/2662-
2011001553 and registered with the Australian and New
Zealand Clinical Trial Register at http://www.anzctr.
org.au/, ACTRN12612000440820, 17th April 2012. All
participants provided written informed consent prior to
study involvement.
Results
Initial study eligibility criteria included an age limit for
participants of 18–70 years. At the recommendation of
the Advisory Group, the upper age limit was raised to
75 years to maximise recruitment and improve study
power. Eighty-five participants were initially recruited.
Twelve declined to participate, one was unavailable at
the time of the study. Of the 72 randomised and invited
to attend a session, 57 participants completed the inter-
vention and 23 participants contributed to study data at
6-months (Fig. 2). At baseline the intervention and
wait-list control groups were similar with regard to
most demographic characteristics and baseline outcomes
(Tables 1 and 2).
Severity of PD as measured at baseline by the PDQ39
was consistent with H&Y stage 2 PD in both interven-
tion and wait-list control groups. Mindfulness, as indi-
cated by FMI scores, was consistent with the normal
Australian population in both groups [25] and, on aver-
age, the wait-list controls were more mindful than the
intervention individuals as indicated by a small yet sig-
nificantly better FMI average score at baseline (t = 2.31,
p = 0.04). Depression and stress average scores at baseline
were consistent with the Australian population [31], but
average anxiety scores were poorer than the Australian
population and consistent with ‘mild’ degree anxiety.
Overall, 16 % (9/56) of all participants had moderate or
greater depression, 16 % (9/55) had moderate stress and
39 % (22/56) had moderate anxiety. The wait-list controls
on average appeared to have poorer depression, stress and
anxiety scores however differences were not significant.
For the four dimensions of locus of control (Internal (I),
Chance, Doctors, Powerful Others), both groups had
similar average scores at baseline, except for one di-
mension, the internal (LOC-I) aspect for which there
was a slight but significant difference between the two
groups (t = −2.06, p = 0.04). Both groups reported simi-
lar average hours of exercise per week and average
nutritional intake of fruit serves per day (Table 2).
7-week impact of intervention, RCT analysis
The analysis at 7-weeks followed that of a standard
two group RCT and change scores compared to base-
line are shown in Table 2. There was no difference in
the primary outcome of PDQ39 since baseline, nor
was there a difference between the intervention and
wait-list control groups.
Mindfulness significantly improved in the interven-
tion group after completing the intervention, showing
Advocat et al. BMC Neurology  (2016) 16:166 Page 5 of 11
a significant difference compared to the wait-list controls
(t = −3.02, p < 0.01) and a medium effect size (Cohen's
d = 0.61). Mental health, as measured by the DASS,
suggested a small increase in depression in the inter-
vention group since baseline, although this difference
was not significantly different between groups (t =
−0.66, p = 0.51). Anxiety scores on average did not
change. However, stress significantly increased in the
intervention group after completing the intervention,
showing a significant increase compared to the wait-
Fig. 2 Flow of participants
Table 1 Baseline characteristics of ESSENCE participants
Baseline characteristics of ESSENCE participants Intervention group Wait-list control group Total (n = 57)
Gender Female, % (n) 66.7 % (16) 51.5 % (17) 57.9 % (33)
Age Age year, mean (sd) 62.8 % (7.6) 63.7 % (8.6) 63.3 (8.1)
range 46–74 39–75 39–75
PD onset Age at onset, mean (sd) 55.8 % (8.8) 55.1 % (10.5) 55.7 (9.9)
range 37–70 33–73 33–73
Current smoker yes, % (n) 0 % (0) 6.1 % (2) 3.5 % (2)
Site Camberwell, % (n) 70.8 % (17) 69.7 % (23) 70.2 % (41)
Essendon, % (n) 26.2 % (7) 30.3 % (10) 29.8 % (17)
COB Born in Australia, % (n) 67 % (16) 79 % (26) 74 % (42)
Marital status Married/defacto, % (n) 71 % (17) 79 % (26) 75 % (43)
Education Above secondary school, % (n) 67 % (16) 85 % (28) 77 % (44)
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Table 2 Main outcome summary. Group 1 received the intervention first and Group 2 was the waitlist control. Group 2 received the intervention after the 7-week measures
were collected





change (95 % CI)
7-week effects (change comparison
between groups)
6-Month follow-up effects (change from
pre-intervention all individuals)
t p Value Effect size t p Value Effect size
Parkinson’s symptoms PDQ39-SI Intervention group 22.2 (12.4) −0.54 (−3.41 to 2.32) −0.89 (−3.71 to 1.93) −0.59 - −1.42 0.16 -
Wait-list control 26.8 (17.5) −1.53 (−3.64 to 0.57) −2.54 (−6.76 to 1.67)
PDQ39-ADL Intervention group 20.8 (14.6) −2.43 (−8.11 to 3.25) −2.54 (−6.87 to 1.80) 0.15 0.89 - −1.80 0.04 b,a 0.23b (small)
Wait-list control 26.9 (23.6) −2.02 (−4.66 to 0.62) −4.17(−10.75 to 2.42)
Mindfulness FMI Intervention group 37.1 (8.2) 4.88 (1.95 to 7.80)a 0.95 (−1.91 to 3.82) −3.02 <0.01a 0.61 (medium) 2.35 0.02a 0.32 (small)




DASS-D Intervention group 4.50 (5.22) 1.92 (0.201 to 3.63)a 0.78 (−0.90 to 2.47) −0.66 0.51 - −0.62 0.54 -
Wait-list control 7.19 (7.83) 1.06 (−0.84 to 2.97) −1.75 (−4.63 to 1.13)
DASS-A Intervention group 7.58 (4.79) 0.33 (−1.67 to 2.34) −0.26 (−1.79 to 1.27) −0.62 0.54 - −0.89 0.38 -
Wait-list control 9.81 (7.56) −0.63 (−2.92 to 1.67) −0.92 (−3.21 to 1.38)
DASS-S Intervention group 8.78 (6.35) 2.17 (0.12 to 4.23)a −1.0 (−2.89 to 0.89) −2.61 0.01a 0.32 (small) −1.80 0.04 b,a 0.27b (small)






LOC-I Intervention group 19.6 (5.5) 0.13 (−1.79 to 2.04) 0.91 (−1.92 to 3.75) 0.99 0.33 - 0.07 0.94 -
Wait-list control 16.5 (5.5) 1.5 (−0.50 to 3.50) −0.78 (−3.19 to 1.62)
LOC-C Intervention group 16.0 (7.2) 1.33 (−1.09 to 3.76) 1.14 (−1.83 to 4.10) −1.69 0.10 - 0.73 0.47 -
Wait-list control 18.6 (6.4) −1.09 (−2.88 to 0.70) 0.39 (−2.75 to 3.53)
LOC-D Intervention group 12.7 (3.7) 0.63 (−0.88 to 2.13) 0.22 (−1.11 to 1.56) −1.80 0.04 b,a 0.28b (small) 0.39 0.70 -
Wait-list control 11.8 (3.3) −0.91 (−1.98 to 0.16) 0.16 (−1.34 to 1.66)
LOC-O Intervention group 8.0 (3.7) 0.13 (−1.38 to 1.63) 0.23 (−1.30 to 1.76) 0.064 0.95 - 0.40 0.69 -
Wait-list control 8.0 (3.0) 0.18 (−0.93 to 1.29) 0.17 (−1.21 to 1.54)
Exercise (hours) Intervention group 1.4 (2.0) 0.38 (−0.22 to 0.97) −0.28 (−1.14 to 0.58) −1.03 0.31 - 0.6717 0.50 -
Wait-list control 1.7 (2.4) −0.32 (−1.41 to 0.77) 0.86 (−0.54 to 2.25)
Nutrition (fruit serves/day) Intervention group 2.2 (1.2) 0 (−.41 to 0.41) 0.32 (−0.05 to 0.69) 0.68 0.50 - −1.80 0.04 b,a 0.28 (small)
Wait-list control 2.4 (1.3) 0.21 (−0.24 to 0.66) 0.29 (−0.31 to 0.90)













list controls (t = −2.61, 0.01) and a small effect size
(Cohen's d = 0.32).
Locus of control measures showed a significant differ-
ence between groups in one dimension only, the internal
aspect (LOC-I). This represented a significant increase
in perceived internal control in the intervention group
after completing the intervention compared to the
wait-list controls (t = −1.8, p = 0.04) and a small effect
size (Cohen's d = 0.28). Health behaviours as mea-
sured by average weekly exercise and daily fruit intake
did not change.
6-month impact of intervention, pre- post analysis
The 6-month analysis differed from the 7-weeks analysis
because all participants had received the intervention
approximately 6 months prior; therefore this analysis
was a before and after examination of scores using
paired t-tests and all participants. Comparing the pri-
mary outcome, PDQ39, there was no measurable differ-
ence at 6 months compared to baseline scores. Of the
eight dimensions of the PDQ39, only one suggested a
possible improvement since baseline had occurred on
average, and this was the activities in daily life (PDQ39-
ADL) sub-category (t = −1.8, p = 0.04) and a small effect
size (Cohen's d = 0.28).
Increased mindfulness on average was measured at 6
months, and this results was significant (t = 2.35, p = 0.02)
with a small effect size (Cohen's d = 0.32).
Decreased stress on average was measured at 6 months,
and this results was significant (t = −1.8, p = 0.04) with a
small effect size (Cohen's d = 0.28).
Health behaviours as measured by average daily fruit
intake improved, and this improvement was significant
(t = −1.8, p = 0.04) with a small effect size (Cohen's
d = 0.28). The average increase in fruit intake corre-
sponded to an extra 1/3 serves extra per day or approxi-
mately 2 serves extra per week.
Adherence analysis
Adherence data was plotted against the study measures.
There were no significant correlations between adher-
ence and any outcome measures during the program or
in the week after the 6-week program. The 6 month dif-
ference scores showed no significant correlations with
adherence except for the depression (DASS-d) measure,
see Fig. 3. The correlation with increased depression and
adherence was weak yet significant (Pearson’s r = 0.3,
p = 0.02) at 6 months.
Discussion
Involvement in a mindfulness-based lifestyle program for
community living adults with H&Y [19] stage 2 PD re-
sulted in a significant increase in mindfulness, stress-
management and improvement in activities of daily living
at 6 month follow up. This positive effect on participant
motor function is not uncommon where behaviour-
change is the central focus of the intervention [32]. A
similar study exploring the effects of the provision of be-
havioural advice on PD symptom management found im-
proved motor performance and reduced tremor amongst
PD participants when compared to a control group [33].
Furthermore, improvements in function may be found
where advice on behaviour-change is delivered within a
supportive group setting [33, 34]. The embedded qualita-
tive study highlighted the group support that was part of
the program had assisted participants in coping with PD,
Fig. 3 Adherence to the program (x-axis) and depression scores (y-axis) at 6 months after program completion. High adherence scores represent
more practice of the program principles. Positive depression change scores represent greater depression at 6 months compared to baseline. The
correlation between increased depression and adherence was weak, yet significant (Pearson’s r = 0.3, p = 0.02
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particularly when groups shared chronic disease manage-
ment ‘tips’ and experiences [35, 36]. The positive group
dynamic of the mindfulness-based lifestyle program deliv-
ered in our study offered opportunities for participants to
share ideas for better disease management and may be
reflected in the significant increase in participants’ ADL
after 6-months from receiving the program. This sus-
tained effect was similarly noted in participant im-
provement in emotional well-being. Positive outcomes
for motor and non-motor dysfunction are particularly
reflected where mindfulness is strongly embedded [37]
and emphasised in intervention programs. Others have
found that interventions which promote personal con-
trol may assist in reducing disability and improving
quality of life in people with PD [38].
Emerging evidence which suggests that mindfulness
may lead to neuroplastic changes of regions in the brain
involved in the regulation of emotion [39, 40] and im-
provements in emotional well-being, particularly stress-
management, anxiety and depression [36, 41, 42] for
people with chronic and neurological disease. Our study
however showed a statistically but not clinically significant
increase in depression following the intervention which
returned to normal at 6 months. In the initial stages of
learning mindfulness people can report more awareness of
depressive symptoms that were already present [43]. This
may be further compounded by negative effects in chan-
ging PD medication dosage [44] and the challenges associ-
ated with adapting to chronic disease, whereby making
adjustments to a person’s social and work life can be stress-
ful or create worry until the benefits of those changes start
to make themselves obvious. It should be noted that sever-
ity of PD symptoms is evidenced to fluctuate throughout
the year [45] with poorer outcomes reported during busy
social periods, such as Christmas, which is when our study
took place. There also appeared to be a correlation be-
tween increased adherence to the program and depression
at 6 months, which may need to be considered as a pos-
sible unwanted outcome in a bigger study.
We also found an increase in stress immediately after
the 6-week program and then significant reduction com-
pared to baseline in stress at 6 months post program,
primarily associated with a recent PD diagnosis. Import-
antly these benefits appeared to be sustainable over lon-
ger periods of time signifying indicating the potential to
improve mental well-being in those recently diagnosed
with PD. Early treatment strategies which aid in the di-
minishment of symptom severity, or the stress associated
in experiencing symptoms, are seen to have more mean-
ingful impacts in improving quality of life [46].
Mindfulness: a feasible therapeutic intervention
We found that mindfulness training may be a feasible
therapeutic intervention within a population of persons
with PD. Previous evidence has suggested greater bene-
fits from mindfulness training particularly for depression
but only after sustained or formal practice [47]. Our
findings indicate that by simply introducing mindfulness
practices, benefits for people with PD can be achieved.
After participating in only six sessions of a holistic lifestyle
program which included up to 20 min of mindfulness train-
ing each week increases in participant mindfulness levels
were found, and, importantly, appeared to be retained lon-
gitudinally. Despite many not engaging in continued formal
practice, positive psychological benefits of the practice are
still found [48]. For participants in this study, knowledge of
mindfulness techniques assisted with better management
of anxiety and stress.
Although ad hoc utilisation of mindfulness techniques
(as opposed to formal practice) appeared to bring benefit
to the study population, it was evident that where mind-
fulness was practiced more regularly and formally partic-
ipants were more likely to report positive improvements
to their well-being. This finding is consistent with the
literature. As mindfulness skills become more integrated
into a regular routine, the greater the benefit in stress
reduction and symptom management [49, 50].
Limitations
An important limitation was the relatively small sample
size of our exploratory study. A larger sample is now
needed to confidently determine significant changes in
patient outcomes. The programme was facilitated by the
author of the model (CH) which may have introduced
some bias. Furthermore, our inclusion criteria and
choice of program location may have limited our study
sample to only include participants of a higher socio-
demographic status and lower disease severity than the
general PD population and may, therefore, reduce the
generalisability of our study findings. This effect is not
uncommon in community based studies recruiting volun-
tary participants [51]. Finally, our primary outcome meas-
ure (PDQ-39) and use of the DASS-21 anxiety sub-scale
may also raise some limitations. Due to the ambiguity of
scoring the PDQ-39 [52, 53], and poor loading and in-
ternal consistency of the DASS-21 anxiety sub-scale, inter-
preting valid change magnitudes amongst a sample with
early stage PD disease severity is challenging and may not
reflect the true changes of disease progression from the
patient perspective [54]. Larger studies should be aware of
these limitation when including the PDQ-31 and DASS-
21 as outcome measures.
Conclusions
This small, community based prospective mixed-method
randomised clinical trial incorporating a before and after
design with a waitlist control provides needed evidence
about the value of incorporating mindfulness training
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into the treatment options available to people with PD.
Our findings suggest that mindfulness-based lifestyle
programs may have great potential to assist participants
in managing ongoing difficulties associated with a
neurological condition such as Parkinson’s disease. In
particular, our study provides suggestive evidence of po-
tential long term benefits for the management of PD
after receiving a mindfulness-based lifestyle program,
when delivered alongside conventional treatment during
early stages of diagnosis. A more definitive study should
be conducted in a larger sample of PD patients to fur-
ther explore the suggested significant increases in activ-
ities of daily living and mindfulness in reducing
outcomes of stress and anxiety in PD patients.
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